These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 7578667

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW.
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [Abstract] [Full Text] [Related]

  • 5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O, Erb F, Goudemand M.
    Encephale; 1995 Mar; 21(6):417-24. PubMed ID: 8674466
    [Abstract] [Full Text] [Related]

  • 6. [Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol].
    Dittert S, Soyka M, Winter C, Möller HJ.
    Fortschr Neurol Psychiatr; 1999 Nov; Suppl 2():S70-3. PubMed ID: 10598340
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G, Safadi G, Beauclair L.
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [Abstract] [Full Text] [Related]

  • 9. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC, Honer WG.
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract] [Full Text] [Related]

  • 10. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
    Vanelle JM, Amorim P, Piketti ML, Bourdel MC, Poirier-Littré MF.
    Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandöl E.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 01; 31(7):1493-9. PubMed ID: 17688987
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ, Arauxo A, Brunet M, Bernardo M, Haro JM, Ferrer J, Gonzalez-Monclus E.
    J Clin Psychopharmacol; 1994 Oct 01; 14(5):303-10. PubMed ID: 7806684
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
    Jibiki I, Kubota T, Fujimoto K, Sakamoto H, Hasegawa M, Furuta H, Yamaguchi N.
    Jpn J Psychiatry Neurol; 1993 Sep 01; 47(3):627-9. PubMed ID: 8301878
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.